Last reviewed · How we verify
Still's disease — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Roactemra | tocilizumab | Roche | Interleukin-6 Receptor Antagonist [EPC] | Interleukin-6 receptor | 2010-01-01 | |
| Anakinra | Kineret | Biovitrum Ab | Interleukin-1 Receptor Antagonist | Interleukin-1 receptor, type I | 2001-01-01 | |
| Kineret | ANAKINRA | Biovitrum Ab | Interleukin-1 Receptor Antagonist [EPC] | Interleukin-1 receptor, type I | 2001-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Biovitrum Ab · 2 drugs in Still's disease
- Roche · 1 drug in Still's disease
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Still's disease:
- Still's disease treatment updates — RSS
- Still's disease treatment updates — Atom
- Still's disease treatment updates — JSON
Cite this brief
Drug Landscape (2026). Still's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/still-s-disease. Accessed 2026-06-10.
Related
- Still's disease full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing